What is the recommended dose of Levocetrizine (levocetirizine) for children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levocetirizine Dosing in Children

For children aged 6-11 years, administer 2.5 mg (½ tablet) once daily in the evening; for children aged 12 years and older, administer 5 mg once daily in the evening. 1

Age-Based Dosing Recommendations

Children 6-11 Years

  • Administer 2.5 mg once daily in the evening 1
  • Do not exceed 2.5 mg in 24 hours 1

Children 12 Years and Older (up to 64 years)

  • Administer 5 mg once daily in the evening 1
  • For less severe symptoms, 2.5 mg once daily may be appropriate 1
  • Do not exceed 5 mg in 24 hours 1

Children Under 6 Years

  • Do not use the standard tablet formulation 1
  • For children aged 1-2 years (12-24 months), research supports 0.125 mg/kg twice daily when using oral solution formulations 2, 3
  • This twice-daily dosing in very young children is necessary due to rapid oral clearance that increases with body weight and age 4, 5

Special Populations

Renal Impairment

  • Do not use levocetirizine in children with kidney disease 1
  • This is a critical contraindication that must be screened for before prescribing 1

Elderly Patients (65+ years)

  • Consult a physician before use 1

Pharmacokinetic Considerations in Young Children

Dosing Rationale for Infants and Toddlers

  • Very young children (12-24 months) require weight-based dosing of 0.125 mg/kg twice daily due to higher weight-normalized clearance compared to adults 4, 2, 5
  • Peak plasma levels occur at approximately 1 hour after administration in toddlers 2
  • Elimination half-life in young children is approximately 4.1 hours, necessitating twice-daily dosing 2
  • This dosing achieves similar drug exposure (AUC) as the adult dose of 5 mg once daily 5

Safety Profile in Young Children

  • Long-term safety (18 months) has been demonstrated in children as young as 12 months at 0.125 mg/kg twice daily 3
  • Adverse event rates are similar to placebo, with most events related to upper respiratory infections or gastroenteritis 3
  • No significant effects on growth, development, or laboratory parameters were observed 3

Clinical Efficacy

Seasonal Allergic Rhinitis

  • In children aged 6-12 years with seasonal allergic rhinitis, levocetirizine 5 mg once daily demonstrated 94.1% relative improvement over placebo in total symptom scores 6
  • Efficacy is sustained over 6 weeks of continuous treatment 6
  • Nasal congestion improved by 77.5% relative to placebo 6

Common Pitfalls to Avoid

  • Never use in children with renal impairment - this is an absolute contraindication 1
  • Do not use standard tablets in children under 6 years - they require liquid formulations with different dosing 1
  • Avoid once-daily dosing in children under 2 years - twice-daily administration is necessary due to rapid clearance 4, 2
  • Do not exceed recommended maximum doses - 2.5 mg/24 hours for ages 6-11, and 5 mg/24 hours for ages 12+ 1
  • Screen for kidney disease before prescribing - this is easily overlooked but critical 1

References

Research

Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile.

International journal of clinical pharmacology and therapeutics, 2005

Research

Safety of levocetirizine treatment in young atopic children: An 18-month study.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2007

Research

Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2005

Research

Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.